Seegene launches CE-marked Allplex MDRO assay
May 28, 2026—Seegene launched its new antimicrobial resistance testing product, the Allplex MDRO assay.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Horiba launches Yumivet VH2500 hematology analyzer
May 27, 2026—Horiba has launched Yumivet, its new veterinary diagnostics brand, and introduced the Yumivet VH2500 hematology analyzer.
FujiFilm, mTuitive partner to integrate technologies
May 26, 2026—FujiFilm Healthcare Americas has announced a strategic partnership with mTuitive under which it will integrate mTuitive’s structured pathology reporting platform with FujiFilm’s Synapse Pathology picture archiving and communication system.
Grundium acquires Visiopharm, adding AI software to its scanner portfolio
May 21, 2026—Finland’s Grundium, backed by U.S.-based health care private equity firm EW Healthcare Partners, has acquired Visiopharm, of Denmark.
Anchor Molecular releases BCR-ABL1 control panels
May 20, 2026—Anchor Molecular launched its BCR-ABL1 control panels designed to support laboratories in monitoring the performance of the quantitative detection of BCR-ABL1 translocation mRNA transcripts.
Streck gets IVD clearance for MDx-Chex controls, launches blood culture tube
May 19, 2026—Streck has received in vitro diagnostic clearance for three MDx-Chex controls for sepsis testing.
FDA OK’s Signatera CDx for muscle-invasive bladder cancer
May 18, 2026—The FDA has approved Natera’s Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq) immunotherapy in muscle-invasive bladder cancer to identify patients who are ctDNA molecular residual disease–positive and may benefit from treatment.
PTS Diagnostics product discontinuation notice
May 13, 2026—The following customer bulletin about A1CNow+ Controls (REF 737) is published at the request of Nova-One Diagnostics.
Streck launches CD-Chex Daily flow cytometry control
May 12, 2026—Streck launched CD-Chex Daily, a ready-to-use quality control for flow cytometry laboratories.
Roche to acquire PathAI for up to $1 billion
May 7, 2026—Roche has entered into a definitive merger agreement to acquire PathAI, extending a partnership that began in 2021 and expanded in 2024 to develop AI-based companion diagnostic algorithms.